VERTEX PHARMACEUTICALS Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory....

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations....

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day....

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]...

Vertex is expanding beyond its cystic fibrosis franchise....

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure....

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development. “Dan's extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex. “His experience navigating periods of high growth and strategic expansion will be especially valuable as Vertex continues to expand, diversify and invest in innovation so we...

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close....

Vertex Pharmaceuticals is showing that it isn't a one-trick pony....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna's mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it....

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die Analysten vom Investmenthaus RBC Capital Markets belassen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) auf "outperform" erhöhen ihr Kursziel von 570 auf 576 USD. [mehr]...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential....

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day....

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability....